{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:19:40Z","timestamp":1788391180497,"version":"build-2803163510"},"reference-count":105,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology\/Oncology Clinics of North America"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.hoc.2026.05.028","type":"journal-article","created":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T22:27:36Z","timestamp":1788388056000},"page":"875-894","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors"],"prefix":"10.1016","volume":"40","author":[{"given":"Adam M.","family":"Fontebasso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey D.","family":"Rytlewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Blay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca A.","family":"Gladdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Breelyn A.","family":"Wilky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.hoc.2026.05.028_bib1","doi-asserted-by":"crossref","first-page":"70","DOI":"10.32074\/1591-951X-213","article-title":"The 2020 WHO Classification of Soft Tissue Tumours: news and perspectives","volume":"113","author":"Sbaraglia","year":"2021","journal-title":"Pathologica"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.028_bib2","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/joim.13717","article-title":"Sarcoma care in the era of precision medicine","volume":"294","author":"Wallander","year":"2023","journal-title":"J Intern Med"},{"key":"10.1016\/j.hoc.2026.05.028_bib3","doi-asserted-by":"crossref","first-page":"9810170","DOI":"10.1155\/2020\/9810170","article-title":"Diagnostic Differences in Expert Second-Opinion Consultation Cases at a Tertiary Sarcoma Center","volume":"2020","author":"Rupani","year":"2020","journal-title":"Sarcoma"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.028_bib4","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/SLA.0000000000001447","article-title":"Variability in Patterns of Recurrence After Resection of Primary Retroperitoneal Sarcoma (RPS): A Report on 1007 Patients From the Multi-institutional Collaborative RPS Working Group","volume":"263","author":"Gronchi","year":"2016","journal-title":"Ann Surg"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.028_bib5","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1016\/S1470-2045(20)30446-0","article-title":"Preoperative radiotherapy plus surgery versus surgery alone for patients with primary retroperitoneal sarcoma (EORTC-62092: STRASS): a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Bonvalot","year":"2020","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.028_bib6","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/SLA.0000000000005492","article-title":"Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma: EORTC-62092 Trial (STRASS) Versus Off-trial (STREXIT) Results","volume":"278","author":"Callegaro","year":"2023","journal-title":"Ann Surg"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.028_bib7","doi-asserted-by":"crossref","first-page":"4573","DOI":"10.1245\/s10434-023-13500-9","article-title":"A Randomized Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Patients with High-Risk Retroperitoneal Sarcoma (STRASS2)","volume":"30","author":"Lambdin","year":"2023","journal-title":"Ann Surg Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.028_bib8","doi-asserted-by":"crossref","first-page":"40","DOI":"10.21037\/cco.2018.08.05","article-title":"Decision-making for palliative versus curative intent treatment of retroperitoneal sarcoma (RPS)","volume":"7","author":"Ng","year":"2018","journal-title":"Chin Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.028_bib9","doi-asserted-by":"crossref","unstructured":"Miwa S, Yamamoto N, Hayashi K, Takeuchi A, Igarashi K, Tsuchiya H. Therapeutic Targets for Bone and Soft-Tissue Sarcomas. International Journal of Molecular Sciences (Internet) 2019 (cited 2023 Nov 17);20(1). Available at: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC6337155\/.","DOI":"10.3390\/ijms20010170"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.028_bib10","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/j.suc.2022.04.001","article-title":"Radiation Therapy for Soft Tissue Sarcoma: Indications, Timing, Benefits, and Consequences","volume":"102","author":"Salerno","year":"2022","journal-title":"Surg Clin North Am"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.028_bib11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/SLA.0b013e3182367aa7","article-title":"A Postoperative Nomogram for Local Recurrence Risk in Extremity Soft Tissue Sarcomas after Limb-Sparing Surgery Without Adjuvant Radiation","volume":"255","author":"Cahlon","year":"2012","journal-title":"Ann Surg"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.028_bib12","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.3390\/jcm10061182","article-title":"Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies","volume":"10","author":"Rathore","year":"2021","journal-title":"J Clin Med"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.028_bib13","doi-asserted-by":"crossref","first-page":"527","DOI":"10.5312\/wjo.v7.i9.527","article-title":"Management of Ewing sarcoma family of tumors: Current scenario and unmet need","volume":"7","author":"Biswas","year":"2016","journal-title":"World J Orthop"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.028_bib14","doi-asserted-by":"crossref","first-page":"2270","DOI":"10.3390\/cancers14092270","article-title":"Optimizing Rhabdomyosarcoma Treatment in Adolescents and Young Adults","volume":"14","author":"Makimoto","year":"2022","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.028_bib15","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/jso.24688","article-title":"Adjuvant chemotherapy in resectable synovial sarcoma","volume":"116","author":"Vining","year":"2017","journal-title":"J Surg Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.028_bib16","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/S1470-2045(14)70063-4","article-title":"Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial","volume":"15","author":"Judson","year":"2014","journal-title":"Lancet Oncol"},{"issue":"9092","key":"10.1016\/j.hoc.2026.05.028_bib17","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.1016\/S0140-6736(97)08165-8","article-title":"Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration","volume":"350","year":"1997","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.028_bib18","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1200\/JCO.2001.19.5.1238","article-title":"Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial","volume":"19","author":"Frustaci","year":"2001","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.028_bib19","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1200\/JCO.2011.37.7218","article-title":"Short, full-dose adjuvant chemotherapy in high-risk adult soft tissue sarcomas: a randomized clinical trial from the Italian Sarcoma Group and the Spanish Sarcoma Group","volume":"30","author":"Gronchi","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.028_bib20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/j.ejca.2018.12.009","article-title":"The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial","volume":"109","author":"Pasquali","year":"2019","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.028_bib21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/1758834017705588","article-title":"Neoadjuvant chemotherapy in soft tissue sarcomas: latest evidence and clinical implications","volume":"9","author":"Pasquali","year":"2017","journal-title":"Ther Adv Med Oncol"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.028_bib22","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/S0360-3016(03)00186-X","article-title":"Neoadjuvant chemotherapy and radiotherapy for large extremity soft-tissue sarcomas","volume":"56","author":"DeLaney","year":"2003","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.hoc.2026.05.028_bib23","article-title":"Sarculator is a Good Model to Predict Survival in Resected Extremity and Trunk Sarcomas in US Patients","author":"Voss","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.028_bib24","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/cncr.33895","article-title":"Neoadjuvant chemotherapy in high-risk soft tissue sarcomas: A Sarculator-based risk stratification analysis of the ISG-STS 1001 randomized trial","volume":"128","author":"Pasquali","year":"2022","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.028_bib25","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/S1470-2045(17)30334-0","article-title":"Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001): an international, open-label, randomised, controlled, phase 3, multicentre trial","volume":"18","author":"Gronchi","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2026.05.028_bib26","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.ejca.2019.11.013","article-title":"The management of desmoid tumours: A joint global consensus-based guideline approach for adult and paediatric patients","volume":"127","year":"2020","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.hoc.2026.05.028_bib27","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejca.2017.06.017","article-title":"Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group","volume":"83","author":"Penel","year":"2017","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.028_bib28","doi-asserted-by":"crossref","first-page":"2587","DOI":"10.1245\/s10434-009-0586-2","article-title":"Desmoid-type fibromatosis: a front-line conservative approach to select patients for surgical treatment","volume":"16","author":"Fiore","year":"2009","journal-title":"Ann Surg Oncol"},{"issue":"25","key":"10.1016\/j.hoc.2026.05.028_bib29","doi-asserted-by":"crossref","first-page":"2417","DOI":"10.1056\/NEJMoa1805052","article-title":"Sorafenib for Advanced and Refractory Desmoid Tumors","volume":"379","author":"Gounder","year":"2018","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.028_bib30","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1097\/CAD.0000000000000474","article-title":"Pazopanib, a promising option for the treatment of aggressive fibromatosis","volume":"28","author":"Szucs","year":"2017","journal-title":"Anti Cancer Drugs"},{"issue":"19","key":"10.1016\/j.hoc.2026.05.028_bib31","doi-asserted-by":"crossref","first-page":"4884","DOI":"10.1158\/1078-0432.CCR-10-1177","article-title":"Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial","volume":"16","author":"Chugh","year":"2010","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.028_bib32","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa2210140","article-title":"Nirogacestat, a \u03b3-Secretase Inhibitor for Desmoid Tumors","volume":"388","author":"Gounder","year":"2023","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.hoc.2026.05.028_bib33","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.3390\/jcm10153230","article-title":"Biology and Management of Dedifferentiated Liposarcoma: State of the Art and Perspectives","volume":"10","author":"Nishio","year":"2021","journal-title":"J Clin Med"},{"issue":"16","key":"10.1016\/j.hoc.2026.05.028_bib34","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1200\/JCO.2012.46.5476","article-title":"Phase II trial of the CDK4 inhibitor PD0332991 in patients with advanced CDK4-amplified well-differentiated or dedifferentiated liposarcoma","volume":"31","author":"Dickson","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2026.05.028_bib35","first-page":"11004","article-title":"Phase 2 study of the CDK4 inhibitor abemaciclib in dedifferentiated liposarcoma","volume":"37","author":"Dickson","year":"2019","journal-title":"J Clin Orthod"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.028_bib36","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/S1470-2045(12)70474-6","article-title":"Effect of the MDM2 antagonist RG7112 on the P53 pathway in patients with MDM2-amplified, well-differentiated or dedifferentiated liposarcoma: an exploratory proof-of-mechanism study","volume":"13","author":"Ray-Coquard","year":"2012","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.028_bib37","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.22.01285","article-title":"A First-in-Human Phase I Study of Milademetan, an MDM2 Inhibitor, in Patients With Advanced Liposarcoma, Solid Tumors, or Lymphomas","volume":"41","author":"Gounder","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.hoc.2026.05.028_bib38","unstructured":"Milademetan Does Not Improve Survival Vs Trabectedin in Liposarcoma (Internet). Cancer Network. 2023 (cited 2023 Nov 11);Available at: https:\/\/www.cancernetwork.com\/view\/milademetan-does-not-improve-survival-vs-trabectedin-in-liposarcoma."},{"issue":"8","key":"10.1016\/j.hoc.2026.05.028_bib39","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1158\/2159-8290.CD-23-0153","article-title":"The MDM2-p53 Antagonist Brigimadlin (BI 907828) in Patients with Advanced or Metastatic Solid Tumors: Results of a Phase Ia, First-in-Human, Dose-Escalation Study","volume":"13","author":"LoRusso","year":"2023","journal-title":"Cancer Discov"},{"key":"10.1016\/j.hoc.2026.05.028_bib40","doi-asserted-by":"crossref","unstructured":"Sch\u00f6ffski P, LoRusso P, Yamamoto N. A PHASE IA\/IB, DOSE-ESCALATION\/EXPANSION STUDY OF THE MDM2-P53 ANTAGONIST BRIGIMADLIN (BI 907828) IN PATIENTS WITH SOLID TUMORS: SAFETY AND EFFICACY IN PATIENTS WITH LIPOSARCOMA. Presented at the Connective Tissue Oncology Society Annual Meeting. Dublin, Ireland. Paper 23. November 1, 2023.","DOI":"10.1200\/JCO.2023.41.16_suppl.11554"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.028_bib41","doi-asserted-by":"crossref","first-page":"621","DOI":"10.2217\/fon-2022-1291","article-title":"Brightline-1: phase II\/III trial of the MDM2-p53 antagonist BI 907828 versus doxorubicin in patients with advanced DDLPS","volume":"19","author":"Sch\u00f6ffski","year":"2023","journal-title":"Future Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.028_bib42","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1158\/1078-0432.CCR-21-1291","article-title":"Co-Targeting of MDM2 and CDK4\/6 with Siremadlin and Ribociclib for the Treatment of Patients with Well-Differentiated or Dedifferentiated Liposarcoma: Results from a Proof-of-Concept, Phase Ib Study","volume":"28","author":"Abdul Razak","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.028_bib43","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/j.ejso.2017.03.011","article-title":"Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate \u2013 The impact of fibrosarcomatous transformation","volume":"43","author":"Rutkowski","year":"2017","journal-title":"Eur J Surg Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.028_bib44","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1056\/NEJMoa2303383","article-title":"Atezolizumab for Advanced Alveolar Soft Part Sarcoma","volume":"389","author":"Chen","year":"2023","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.hoc.2026.05.028_bib45","doi-asserted-by":"crossref","first-page":"5233","DOI":"10.1158\/1078-0432.CCR-17-3766","article-title":"Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma","volume":"24","author":"Chi","year":"2018","journal-title":"Clin Cancer Res"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.028_bib46","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S1470-2045(19)30215-3","article-title":"Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial","volume":"20","author":"Judson","year":"2019","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.028_bib47","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/annonc\/mdq644","article-title":"Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect","volume":"22","author":"Stacchiotti","year":"2011","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.028_bib48","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1634\/theoncologist.2017-0161","article-title":"Activity of Pazopanib and Trabectedin in Advanced Alveolar Soft Part Sarcoma","volume":"23","author":"Stacchiotti","year":"2018","journal-title":"Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.028_bib49","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S1470-2045(19)30153-6","article-title":"Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: a single-centre, single-arm, phase 2 trial","volume":"20","author":"Wilky","year":"2019","journal-title":"Lancet Oncol"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2026.05.028_bib50","doi-asserted-by":"crossref","first-page":"11516","DOI":"10.1200\/JCO.2020.38.15_suppl.11516","article-title":"Long-term follow-up for duration of response (DoR) after weekly nab-sirolimus in patients with advanced malignant perivascular epithelioid cell tumors (PEComa): Results from a registrational open-label phase II trial","volume":"38","author":"Wagner","year":"2020","journal-title":"AMPECT. JCO"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.028_bib51","first-page":"3663","article-title":"A retrospective study of patients with malignant PEComa receiving treatment with sirolimus or temsirolimus: the Royal Marsden Hospital experience","volume":"34","author":"Benson","year":"2014","journal-title":"Anticancer Res"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.05.028_bib52","first-page":"11515","article-title":"RINGSIDE phase 2\/3 trial of AL102 for treatment of desmoid tumors (DT): Phase 2 results","volume":"41","author":"Gounder","year":"2023","journal-title":"J Clin Orthod"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.028_bib53","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/S1470-2045(19)30663-1","article-title":"Denosumab in patients with giant-cell tumour of bone: a multicentre, open-label, phase 2 study","volume":"20","author":"Chawla","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10197","key":"10.1016\/j.hoc.2026.05.028_bib54","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/S0140-6736(19)30764-0","article-title":"Pexidartinib for advanced tenosynovial giant cell tumor: results of the randomized phase 3 ENLIVEN study","volume":"394","author":"Tap","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.hoc.2026.05.028_bib55","article-title":"The MOTION study: a randomized, Phase III study of vimseltinib for the treatment of tenosynovial giant cell tumor","author":"Tap","year":"2023","journal-title":"Future Oncol"},{"key":"10.1016\/j.hoc.2026.05.028_bib56","doi-asserted-by":"crossref","first-page":"14551","DOI":"10.1038\/s41598-019-51211-y","article-title":"Long-term efficacy of imatinib mesylate in patients with advanced Tenosynovial Giant Cell Tumor","volume":"9","author":"Verspoor","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.hoc.2026.05.028_bib57","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ejca.2021.07.016","article-title":"Long-term efficacy update of crizotinib in patients with advanced, inoperable inflammatory myofibroblastic tumour from EORTC trial 90101 CREATE","volume":"156","author":"Sch\u00f6ffski","year":"2021","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.028_bib58","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1056\/NEJMoa1704795","article-title":"Alectinib versus Crizotinib in Untreated ALK-Positive Non\u2013Small-Cell Lung Cancer","volume":"377","author":"Peters","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.hoc.2026.05.028_bib59","doi-asserted-by":"crossref","unstructured":"Sn G, La B, Cj L, et al. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial. The Lancet Oncology (Internet) 2016 (cited 2023 Nov 13);17(12). Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/27836716\/.","DOI":"10.1016\/S1470-2045(16)30392-8"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.028_bib60","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1093\/annonc\/mdw405","article-title":"Chromoplectic TPM3-ALK rearrangement in a patient with inflammatory myofibroblastic tumor who responded to ceritinib after progression on crizotinib","volume":"27","author":"Mansfield","year":"2016","journal-title":"Ann Oncol"},{"issue":"10","key":"10.1016\/j.hoc.2026.05.028_bib61","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1097\/CAD.0000000000000994","article-title":"Lorlatinib for the treatment of inflammatory myofibroblastic tumour with TPM4-ALK fusion following failure of entrectinib","volume":"31","author":"Wong","year":"2020","journal-title":"Anti Cancer Drugs"},{"issue":"21","key":"10.1016\/j.hoc.2026.05.028_bib62","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1002\/cncr.26098","article-title":"Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor","volume":"117","author":"Park","year":"2011","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.028_bib63","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1159\/000486623","article-title":"Efficacy and Safety of Pazopanib for Recurrent or Metastatic Solitary Fibrous Tumor","volume":"94","author":"Ebata","year":"2018","journal-title":"Oncology"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2026.05.028_bib64","first-page":"11003","article-title":"Safety and efficacy of tazemetostat, a first-in-class EZH2 inhibitor, in patients (pts) with epithelioid sarcoma (ES) (NCT02601950)","volume":"37","author":"Stacchiotti","year":"2019","journal-title":"J Clin Orthod"},{"issue":"15","key":"10.1016\/j.hoc.2026.05.028_bib65","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.1200\/JCO.19.02492","article-title":"Phase I Study of the Mutant IDH1 Inhibitor Ivosidenib: Safety and Clinical Activity in Patients With Advanced Chondrosarcoma","volume":"38","author":"Tap","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.hoc.2026.05.028_bib66","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","author":"Stein","year":"2017","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.05.028_bib67","first-page":"TPS11582","article-title":"A randomized, placebo-controlled, phase 2 trial of INBRX-109 in unresectable or metastatic conventional chondrosarcoma","volume":"40","author":"Chawla","year":"2022","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.028_bib68","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1002\/cncr.32515","article-title":"Results of a prospective phase 2 study of pazopanib in patients with surgically unresectable or metastatic chondrosarcoma","volume":"126","author":"Chow","year":"2020","journal-title":"Cancer"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2026.05.028_bib69","first-page":"11521","article-title":"Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid\/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis","volume":"39","author":"D\u2019Angelo","year":"2021","journal-title":"J Clin Orthod"},{"issue":"16_suppl","key":"10.1016\/j.hoc.2026.05.028_bib70","first-page":"11563","article-title":"The SPEARHEAD-1 trial of afamitresgene autoleucel (afami-cel [formerly ADP-A2M4]): Analysis of overall survival in advanced synovial sarcoma","volume":"41","author":"Van Tine","year":"2023","journal-title":"J Clin Orthod"},{"issue":"15_suppl","key":"10.1016\/j.hoc.2026.05.028_bib71","first-page":"11503","article-title":"P10015\/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE)","volume":"39","author":"Schuetze","year":"2021","journal-title":"J Clin Orthod"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.028_bib72","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1186\/s40425-019-0689-7","article-title":"Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution","volume":"7","author":"Florou","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.028_bib73","doi-asserted-by":"crossref","first-page":"e002990","DOI":"10.1136\/jitc-2021-002990","article-title":"Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART)","volume":"9","author":"Wagner","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"2","key":"10.1016\/j.hoc.2026.05.028_bib74","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1\u20132 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.028_bib75","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK Fusion\u2013Positive Cancers in Adults and Children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"issue":"15","key":"10.1016\/j.hoc.2026.05.028_bib76","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1912735","article-title":"Selumetinib in Children with Inoperable Plexiform Neurofibromas","volume":"382","author":"Gross","year":"2020","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.hoc.2026.05.028_bib77","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/j.annonc.2022.05.519","article-title":"Pembrolizumab in microsatellite instability high or mismatch repair deficient cancers: updated analysis from the phase II KEYNOTE-158 study","volume":"33","author":"Maio","year":"2022","journal-title":"Ann Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2026.05.028_bib78","doi-asserted-by":"crossref","first-page":"5078","DOI":"10.1158\/1078-0432.CCR-20-1706","article-title":"Gastrointestinal Stromal Tumor: Challenges and Opportunities for a New Decade","volume":"26","author":"Serrano","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"15","key":"10.1016\/j.hoc.2026.05.028_bib79","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/cncr.28669","article-title":"Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib","volume":"120","author":"Joensuu","year":"2014","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.hoc.2026.05.028_bib80","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.soc.2022.03.002","article-title":"Relevant Trials Update in Sarcomas and Gastrointestinal Stromal Tumors: What Surgeons Should Know","volume":"31","author":"Callegaro","year":"2022","journal-title":"Surg Oncol Clin N Am"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.028_bib81","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.yasu.2014.05.014","article-title":"GIST tumors: Who should get imatinib and for how long?","volume":"48","author":"Balachandran","year":"2014","journal-title":"Adv Surg"},{"issue":"5","key":"10.1016\/j.hoc.2026.05.028_bib82","doi-asserted-by":"crossref","first-page":"4648","DOI":"10.3390\/curroncol30050351","article-title":"Precision Oncology in Gastrointestinal Stromal Tumors","volume":"30","author":"Mechahougui","year":"2023","journal-title":"Curr Oncol"},{"issue":"19","key":"10.1016\/j.hoc.2026.05.028_bib83","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1158\/1078-0432.CCR-21-1221","article-title":"Location of Gastrointestinal Stromal Tumor (GIST) in the Stomach Predicts Tumor Mutation Profile and Drug Sensitivity","volume":"27","author":"Sharma","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.028_bib84","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1245\/s10434-023-13519-y","article-title":"Surgical Management of Germline Gastrointestinal Stromal Tumor","volume":"30","author":"Kwak","year":"2023","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.hoc.2026.05.028_bib85","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s13053-016-0055-4","article-title":"Syndromic gastrointestinal stromal tumors","volume":"14","author":"Ricci","year":"2016","journal-title":"Hered Cancer Clin Pract"},{"issue":"11","key":"10.1016\/j.hoc.2026.05.028_bib86","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1093\/annonc\/mds198","article-title":"Adjuvant therapy in primary GIST: state-of-the-art","volume":"23","author":"Reichardt","year":"2012","journal-title":"Ann Oncol"},{"issue":"8","key":"10.1016\/j.hoc.2026.05.028_bib87","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1001\/jamaoncol.2020.2091","article-title":"Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors","volume":"6","author":"Joensuu","year":"2020","journal-title":"JAMA Oncol"},{"issue":"12","key":"10.1016\/j.hoc.2026.05.028_bib88","doi-asserted-by":"crossref","first-page":"1265","DOI":"10.1001\/jama.2012.347","article-title":"One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial","volume":"307","author":"Joensuu","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.hoc.2026.05.028_bib89","doi-asserted-by":"crossref","first-page":"672500","DOI":"10.3389\/fonc.2021.672500","article-title":"Early and Next-Generation KIT\/PDGFRA Kinase Inhibitors and the Future of Treatment for Advanced Gastrointestinal Stromal Tumor","volume":"11","author":"Bauer","year":"2021","journal-title":"Front Oncol"},{"issue":"33","key":"10.1016\/j.hoc.2026.05.028_bib90","doi-asserted-by":"crossref","first-page":"5360","DOI":"10.1200\/JCO.2008.17.4284","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"issue":"9544","key":"10.1016\/j.hoc.2026.05.028_bib91","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/S0140-6736(06)69446-4","article-title":"Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial","volume":"368","author":"Demetri","year":"2006","journal-title":"Lancet"},{"issue":"9863","key":"10.1016\/j.hoc.2026.05.028_bib92","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0140-6736(12)61857-1","article-title":"Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial","volume":"381","author":"Demetri","year":"2013","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.028_bib93","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/S1470-2045(20)30168-6","article-title":"Ripretinib in patients with advanced gastrointestinal stromal tumours (INVICTUS): a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Blay","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.hoc.2026.05.028_bib94","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ejca.2021.07.010","article-title":"Ripretinib intrapatient dose escalation after disease progression provides clinically meaningful outcomes in advanced gastrointestinal stromal tumour","volume":"155","author":"George","year":"2021","journal-title":"Eur J Cancer"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.028_bib95","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/S1470-2045(20)30269-2","article-title":"Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial","volume":"21","author":"Heinrich","year":"2020","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.hoc.2026.05.028_bib96","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/j.annonc.2023.04.006","article-title":"Circulating tumor DNA analysis of the phase III VOYAGER trial: KIT mutational landscape and outcomes in patients with advanced gastrointestinal stromal tumor treated with avapritinib or regorafenib","volume":"34","author":"Serrano","year":"2023","journal-title":"Ann Oncol"},{"key":"10.1016\/j.hoc.2026.05.028_bib97","doi-asserted-by":"crossref","first-page":"927587","DOI":"10.3389\/fonc.2022.927587","article-title":"An overview of agents and treatments for PDGFRA-mutated gastrointestinal stromal tumors","volume":"12","author":"Sun","year":"2022","journal-title":"Front Oncol"},{"issue":"34","key":"10.1016\/j.hoc.2026.05.028_bib98","doi-asserted-by":"crossref","first-page":"3918","DOI":"10.1200\/JCO.22.00294","article-title":"Ripretinib Versus Sunitinib in Patients With Advanced Gastrointestinal Stromal Tumor After Treatment With Imatinib (INTRIGUE): A Randomized, Open-Label, Phase III Trial","volume":"40","author":"Bauer","year":"2022","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.hoc.2026.05.028_bib99","doi-asserted-by":"crossref","first-page":"3128","DOI":"10.1200\/JCO.21.00217","article-title":"Avapritinib Versus Regorafenib in Locally Advanced Unresectable or Metastatic GI Stromal Tumor: A Randomized, Open-Label Phase III Study","volume":"39","author":"Kang","year":"2021","journal-title":"J Clin Oncol"},{"issue":"36_suppl","key":"10.1016\/j.hoc.2026.05.028_bib100","first-page":"397784","article-title":"Mutational heterogeneity of imatinib resistance and efficacy of ripretinib vs sunitinib in patients with gastrointestinal stromal tumor: ctDNA analysis from INTRIGUE","volume":"41","author":"Bauer","year":"2023","journal-title":"J Clin Orthod"},{"issue":"4","key":"10.1016\/j.hoc.2026.05.028_bib101","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/CCO.0000000000000089","article-title":"Gastrointestinal stromal tumors in the setting of multiple tumor syndromes","volume":"26","author":"Burgoyne","year":"2014","journal-title":"Curr Opin Oncol"},{"issue":"1","key":"10.1016\/j.hoc.2026.05.028_bib102","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1158\/1078-0432.CCR-21-2092","article-title":"Establishment of Patient-Derived Succinate Dehydrogenase-Deficient Gastrointestinal Stromal Tumor Models for Predicting Therapeutic Response","volume":"28","author":"Yebra","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.hoc.2026.05.028_bib103","unstructured":"Burgoyne A, Heinrich MC, von Mehren M, et al. Paper 83. Connective Tissue Oncology Society Annual Meeting. November 4, 2023. Dublin, Ireland: 2023."},{"issue":"7781","key":"10.1016\/j.hoc.2026.05.028_bib104","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-019-1668-3","article-title":"Altered chromosomal topology drives oncogenic programs in SDH-deficient GISTs","volume":"575","author":"Flavahan","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.hoc.2026.05.028_bib105","unstructured":"Merriam P, Mazzola E, Chi P, et al. Paper 84. Connective Tissue Oncology Society Annual Meeting. November 4, 2023. Dublin, Ireland: 2023."}],"container-title":["Hematology\/Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000705?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889858826000705?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T23:01:20Z","timestamp":1788390080000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889858826000705"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":105,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S0889858826000705"],"URL":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.028","relation":{},"ISSN":["0889-8588"],"issn-type":[{"value":"0889-8588","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Precision Oncology in Soft Tissue Sarcomas and Gastrointestinal Stromal Tumors","name":"articletitle","label":"Article Title"},{"value":"Hematology\/Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hoc.2026.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}